Based on these findings, we propose exploring a triple-combination strategy for ARID1A- hypermethylated gastric cancer: 5-aza-CdR to potentially restore tumor suppression and block PD-L1 upregulation, PD-1 inhibitors to counteract immune evasion, and AKT inhibitors (e.g., capivasertib) to mitigate residual pathway activation. The gene discussed is ARID1A; the disease is gastric cancer.